Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

uate

-------------------------------------------------------------------------

* still on study. CR=complete response,

PR=partial response, SD=stable disease,

PD=progressive disease

The Phase I trial has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously to patients with paclitaxel and carboplatin every three weeks. In this portion of the trial, standard dosages of paclitaxel and carboplatin are delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as melanoma, lung and ovarian that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The Phase II trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.

The poster will be available today on the Oncolytics website at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... benchmarking survey on kinase profiling carried out in ... details of the breakdown of the responses for ... the future (2015). It also highlights some interesting ... survey groupings. Two bottom-up models were developed to ...
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
(Date:5/24/2013)... City, OK (PRWEB) May 24, 2013 The ... of casualties. And following its ravage, the mayor of Moore, ... bill for new houses, said a report from cnn.com. Reaching ... the tornado victims complimentary Molderizer and Safe Shield to counter ... to the report published on May 22, 2013, caused 24 ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly traded ... development, sales and marketing of premium branded highly ... it is awarding exclusive Vestiage territories in the ... Illuminating Facial Care. Qualified applicants can request an ... to info(at)vestiageinc(dot)com and putting RELUMA in the "Subject" ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5
... how big a software project was, and we will often ... have units of time. How big was another 11,000-hour project ... 11,000-hour project that produced only a little bitof software, but ... software size, but without a measurable ounce of software, we're ...
... is the 10th in a series of articles on developing ... , Madison, Wis. - In Step 9 ... we focus specifically on the federal laws. , ,Any ... state and federal securities laws and regulations. Of equal importance ...
... adoption of healthcare information technology continues its slow but steady march, ... ,The progress that has been made, and the issues still to ... Conference set for May 9 and 10 at the Fluno ... , Dr. Barry Chaiken Dr. Barry Chaiken, associate chief ...
Cached Biology Technology:Defining the X-factor: What is an ounce of software worth? 2Defining the X-factor: What is an ounce of software worth? 3Defining the X-factor: What is an ounce of software worth? 4Early Stage 10: The nuances of federal laws 2Early Stage 10: The nuances of federal laws 3Early Stage 10: The nuances of federal laws 4Early Stage 10: The nuances of federal laws 5Digital Healthcare Conference 2007: Mounting obstacles for health IT 2Digital Healthcare Conference 2007: Mounting obstacles for health IT 3
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... most popular fruit, can be made both better-tasting and ... , "Working with GM tomatoes that are different ... specific compound, allows us to pinpoint exactly how to ... the John Innes Centre. , The research could also ... shelf life characteristics because even higher levels of the ...
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than 165 ... intellectual property at PNNL,s annual Intellectual Property Commercialization ... Department of Energy national laboratory named materials scientist ... work developing battery materials that can store large ... grid, and reduce the time it takes to ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
... Boys and girls have put many of the trappings of teenagerhood ... least some of the brain resculpting that characterizes the decade of ... findings in a new study that measured brainwaves of subjects in ... the kinds of neurological changes underway in a teen brain is ...
... at Washington State University Spokane offers hope to those ... which was published online this week in the journal ... nerve damage incurred during childhood can improve with intensive ... there isn,t just a one-year window for facial rehabilitation, ...
Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2Study: Pace of brain development still strong in late teens 2WSU study expands time window for facial nerve rehabilitation 2
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... assays. The TUNEL-based assay kit provides complete ... for convenient detection of DNA fragmentation in ... offers an one-step labeling of apoptotic cells. ... hallmark of apoptosis in mammalian cells. MBLs ...
Biology Products: